EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that it signed a memorandum of understanding (MOU) with Kangbuk Samsung Hospital to develop effective education programs of wearable insulin pump EOPatch for people with Type 2 diabetes. The MOU includes EOFlow and Kangbuk Samsung Hospital to cooperate together for education for the use of wearable insulin pumps, such as ▲ developing wearable insulin pump education materials and programs ▲ establishing an efficient educational program through research ▲ expanding medical staff experience through training courses and seminars.
Kangbuk Samsung Hospital is also conducting clinical trials of EOPatch on people with type 2 diabetes in Korea. This pioneering study aims to demonstrate and validate efficacy of EOPatch for Type 2 diabetes therapy. Along with clinical trials, Kangbuk Samsung Hospital aims to develop effective education programs.



For more information, please check out the news on Hankyung BIO Insight (in Korean only): https://www.hankyung.com/it/article/202201135277i